KEAP1 and neoplasm: These studies show that inactivating KEAP1 mutations promote tumor growth and migration through activating NRF2 mediated transcription of antioxidant response genes like NQO1 and mutations in KEAP1/NRF2 are potential drivers of clinical treatment resistance to a variety of agents.